Natallia Rameika

NAT2 activity increases cytotoxicity of anthracycline antibiotics and HDAC inhibitors

Rameika, Natallia; Tsiara, Ioanna; Zhang, Xiaonan; Haberek, Wawrzyniec et al.

Part of Biochimica et Biophysica Acta - Molecular Basis of Disease, 2025

• DOI for NAT2 activity increases cytotoxicity of anthracycline antibiotics and HDAC inhibitors
• Download full text (pdf) of NAT2 activity increases cytotoxicity of anthracycline antibiotics and HDAC inhibitors

Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib

Zhang, Xiaonan; Rameika, Natallia; Zhong, Lei; Veanes, Margus et al.

Part of EBioMedicine, 2024

• DOI for Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib
• Download full text (pdf) of Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib

Next generation pan-cancer blood proteome profiling using proximity extension assay

Alvez, Maria Bueno; Edfors, Fredrik; von Feilitzen, Kalle; Zwahlen, Martin et al.

Part of Nature Communications, 2023

• DOI for Next generation pan-cancer blood proteome profiling using proximity extension assay
• Download full text (pdf) of Next generation pan-cancer blood proteome profiling using proximity extension assay

Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer

Rendo, Verónica; Kundu, Snehangshu; Rameika, Natallia; Ljungström, Viktor et al.

Part of Scientific Reports, 2020

• DOI for Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer
• Download full text (pdf) of Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer

Composite proteomic and metabolomic plasma biomarkers for detection of colorectal, lung and ovarian cancers

Åkerrén Ögren, Jim; Ekström, Joakim; Rameika, Natallia; Torell, Emma et al.

Part of Molecular Cancer, 2026

• DOI for Composite proteomic and metabolomic plasma biomarkers for detection of colorectal, lung and ovarian cancers
• Download full text (pdf) of Composite proteomic and metabolomic plasma biomarkers for detection of colorectal, lung and ovarian cancers

NAT2 activity increases cytotoxicity of anthracycline antibiotics and HDAC inhibitors

Rameika, Natallia; Tsiara, Ioanna; Zhang, Xiaonan; Haberek, Wawrzyniec et al.

Part of Biochimica et Biophysica Acta - Molecular Basis of Disease, 2025

• DOI for NAT2 activity increases cytotoxicity of anthracycline antibiotics and HDAC inhibitors
• Download full text (pdf) of NAT2 activity increases cytotoxicity of anthracycline antibiotics and HDAC inhibitors

A human pan-disease blood atlas of the circulating proteome

Álvez, María Bueno; Bergström, Sofia; Kenrick, Josefin; Johansson, Emil et al.

Part of Science, 2025

• DOI for A human pan-disease blood atlas of the circulating proteome

Identification of a small molecule targeting EPLIN as a novel strategy for the treatment of pediatric neuroblastoma and medulloblastoma

Lindell, Emma; Guo, Jing; Zhao, Miao; Rameika, Natallia et al.

Part of Cell Death and Disease, 2025

• DOI for Identification of a small molecule targeting EPLIN as a novel strategy for the treatment of pediatric neuroblastoma and medulloblastoma
• Download full text (pdf) of Identification of a small molecule targeting EPLIN as a novel strategy for the treatment of pediatric neuroblastoma and medulloblastoma

Targeting loss of heterozygosity in cancer

Rameika, Natallia

2025

• Download full text (pdf) of Targeting loss of heterozygosity in cancer

Composite proteomic and metabolomic plasma biomarkers for detection of colorectal, lung and ovarian cancers

Åkerrén Ögren, Jim; Ekström, Joakim; Rameika, Natallia; Torell, Emma et al.

Part of Molecular Cancer, 2026

• DOI for Composite proteomic and metabolomic plasma biomarkers for detection of colorectal, lung and ovarian cancers
• Download full text (pdf) of Composite proteomic and metabolomic plasma biomarkers for detection of colorectal, lung and ovarian cancers

NAT2 activity increases cytotoxicity of anthracycline antibiotics and HDAC inhibitors

Rameika, Natallia; Tsiara, Ioanna; Zhang, Xiaonan; Haberek, Wawrzyniec et al.

Part of Biochimica et Biophysica Acta - Molecular Basis of Disease, 2025

• DOI for NAT2 activity increases cytotoxicity of anthracycline antibiotics and HDAC inhibitors
• Download full text (pdf) of NAT2 activity increases cytotoxicity of anthracycline antibiotics and HDAC inhibitors

A human pan-disease blood atlas of the circulating proteome

Álvez, María Bueno; Bergström, Sofia; Kenrick, Josefin; Johansson, Emil et al.

Part of Science, 2025

• DOI for A human pan-disease blood atlas of the circulating proteome

Identification of a small molecule targeting EPLIN as a novel strategy for the treatment of pediatric neuroblastoma and medulloblastoma

Lindell, Emma; Guo, Jing; Zhao, Miao; Rameika, Natallia et al.

Part of Cell Death and Disease, 2025

• DOI for Identification of a small molecule targeting EPLIN as a novel strategy for the treatment of pediatric neuroblastoma and medulloblastoma
• Download full text (pdf) of Identification of a small molecule targeting EPLIN as a novel strategy for the treatment of pediatric neuroblastoma and medulloblastoma

Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib

Zhang, Xiaonan; Rameika, Natallia; Zhong, Lei; Veanes, Margus et al.

Part of EBioMedicine, 2024

• DOI for Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib
• Download full text (pdf) of Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib

Next generation pan-cancer blood proteome profiling using proximity extension assay

Alvez, Maria Bueno; Edfors, Fredrik; von Feilitzen, Kalle; Zwahlen, Martin et al.

Part of Nature Communications, 2023

• DOI for Next generation pan-cancer blood proteome profiling using proximity extension assay
• Download full text (pdf) of Next generation pan-cancer blood proteome profiling using proximity extension assay

Enhanced cytotoxicity of a novel family of ATPase inhibitors in colorectal cancer cells with high NAT2 activity

Zhang, Xiaonan; Akcan, Ece; Correia, Mario S. P.; Rameika, Natallia et al.

Part of Biochemical Pharmacology, 2022

• DOI for Enhanced cytotoxicity of a novel family of ATPase inhibitors in colorectal cancer cells with high NAT2 activity
• Download full text (pdf) of Enhanced cytotoxicity of a novel family of ATPase inhibitors in colorectal cancer cells with high NAT2 activity

Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer

Rendo, Verónica; Kundu, Snehangshu; Rameika, Natallia; Ljungström, Viktor et al.

Part of Scientific Reports, 2020

• DOI for Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer
• Download full text (pdf) of Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer

Targeting loss of heterozygosity in cancer

Rameika, Natallia

2025

• Download full text (pdf) of Targeting loss of heterozygosity in cancer

Identification of novel target genes for LOH-based cancer therapy

Rameika, Natallia; Veanes, Margus; Akcan, Ece; Kundu, Snehangshu et al.

Novel anti-cancer agents targeting NAT2 loss in colorectal cancer

Rameika, Natallia; Tsiara, Ioanna; Haberek, Wawrzyniec; Akcan, Ece et al.